HC Wainwright Increases Harrow (NASDAQ:HROW) Price Target to $70.00

Harrow (NASDAQ:HROW) had its target price increased by equities researchers at HC Wainwright from $69.00 to $70.00 in a report released on Wednesday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 93.53% from the company’s previous close. HC Wainwright also issued estimates for Harrow’s Q3 2026 earnings at $0.20 EPS and Q4 2026 earnings at $0.40 EPS.

Several other brokerages have also weighed in on HROW. Cantor Fitzgerald reissued an “overweight” rating and set a $94.00 price objective on shares of Harrow in a report on Tuesday, November 11th. William Blair reiterated an “outperform” rating on shares of Harrow in a research note on Tuesday. Zacks Research lowered Harrow from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Finally, LADENBURG THALM/SH SH lifted their target price on shares of Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $71.14.

Harrow Stock Performance

NASDAQ HROW opened at $36.17 on Wednesday. The company has a market capitalization of $1.35 billion, a PE ratio of -212.75 and a beta of 0.05. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.52 and a current ratio of 2.20. Harrow has a 52-week low of $20.85 and a 52-week high of $54.85. The company has a 50-day simple moving average of $47.92 and a 200 day simple moving average of $43.71.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, March 2nd. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.23). Harrow had a negative net margin of 1.89% and a positive return on equity of 36.51%. The company had revenue of $89.09 million for the quarter, compared to the consensus estimate of $88.42 million. On average, research analysts predict that Harrow will post -0.53 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in HROW. Larson Financial Group LLC lifted its holdings in shares of Harrow by 13.1% in the fourth quarter. Larson Financial Group LLC now owns 2,446 shares of the company’s stock worth $120,000 after buying an additional 284 shares in the last quarter. Teacher Retirement System of Texas grew its stake in Harrow by 4.1% during the second quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company’s stock valued at $259,000 after acquiring an additional 332 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Harrow by 2.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock worth $505,000 after acquiring an additional 341 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Harrow by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after purchasing an additional 369 shares in the last quarter. Finally, Captrust Financial Advisors lifted its stake in Harrow by 0.5% in the 4th quarter. Captrust Financial Advisors now owns 69,959 shares of the company’s stock worth $3,428,000 after purchasing an additional 376 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow News Roundup

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and raised its price target to $70, signaling continued upside from that shop despite recent volatility. H.C. Wainwright PT Raised
• Positive Sentiment: Company reported record 2025 results and set a 2026 outlook, underscoring underlying revenue momentum that management says supports growth investments. Record 2025 Results
• Positive Sentiment: Management outlined a $350M–$365M 2026 revenue goal tied to salesforce expansion and pipeline progress — a constructive guide for top-line growth if execution holds. 2026 Revenue Goal
• Neutral Sentiment: Cantor Fitzgerald trimmed its price target slightly (from $94 to $91) but remains Overweight, leaving a large implied upside from current levels — mixed signal on conviction. Cantor Fitzgerald PT Change
• Neutral Sentiment: Management will present at the Leerink Global Healthcare Conference (Mar 10), giving investors another opportunity for management commentary and Q&A. Leerink Presentation
• Negative Sentiment: Zacks Research downgraded Harrow from Hold to Strong Sell, increasing bearish analyst pressure and likely contributing to near-term selling. Zacks Downgrade Coverage
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS forecasts (Q3: $0.29 → $0.20; Q4: $0.51 → $0.40), reflecting weaker near-term profit expectations even while the firm keeps a Buy rating. HC Wainwright Estimate Cuts
• Negative Sentiment: Investors reacted to a disappointing Q4 EPS print (reported EPS well below consensus), margin pressure, and warnings about higher S&M and interest expense; analysts and outlets highlighted valuation and leverage concerns. Coverage and analyses explain the post-earnings selloff. Earnings Transcript SA Analysis Shares Gap Down

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.